176 results on '"Masri"'
Search Results
2. Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy
3. Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy
4. Safety and Efficacy of Metabolic Modulation With Ninerafaxstat in Patients With Nonobstructive Hypertrophic Cardiomyopathy
5. Stratifying Disease Progression in Patients With Cardiac ATTR Amyloidosis
6. 2022 ACC/AHA Key Data Elements and Definitions for Chest Pain and Acute Myocardial Infarction: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Data Standards
7. Turning Meters into Years: Walking to Survive Transthyretin Cardiac Amyloidosis
8. 2022 ACC/AHA Key Data Elements and Definitions for Chest Pain and Acute Myocardial Infarction
9. Genetic Cardiomyopathy Masquerading as Cardiac Sarcoidosis
10. AFICAMTEN IN PATIENTS WITH SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (REDWOOD-HCM COHORT 4)
11. EFFECT OF SEPTAL MYECTOMY ON EXERCISE PARAMETERS IN PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: A PROSPECTIVE PAIRED PRE-POST HEMODYNAMIC STRESS ECHOCARDIOGRAPHY STUDY
12. RECURRENCE OF VENTRICULAR ARRHYTHMIAS IN CARDIAC SARCOIDOSIS
13. TRENDS IN MORTALITY AND MORBIDITY AFTER MYOCARDIAL INFARCTION: A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS BETWEEN 1980-2019.
14. LONG-TERM SAFETY AND EFFICACY OF MAVACAMTEN IN PATIENTS (PTS) WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM): UPDATED RESULTS FROM THE PIONEER-OLE STUDY
15. LONG-TERM EFFICACY AND SAFETY OF AFICAMTEN IN PATIENTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
16. 96-WEEK CARDIAC MAGNETIC RESONANCE (CMR) RESULTS OF TREATMENT WITH MAVACAMTEN FROM THE EXPLORER COHORT OF THE MAVA-LONG-TERM EXTENSION (LTE) STUDY IN PATIENTS (PTS) WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM)
17. Genetic Cardiomyopathy Masquerading as Cardiac Sarcoidosis
18. Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
19. A New Dawn in HCM
20. TCT-435 Clinical Outcomes in Patients With Concurrent Calcific Aortic Stenosis and Transthyretin Cardiac Amyloidosis
21. Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
22. AFICAMTEN IN PATIENTS WITH SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (REDWOOD-HCM COHORT 4)
23. RECURRENCE OF VENTRICULAR ARRHYTHMIAS IN CARDIAC SARCOIDOSIS
24. EFFECT OF SEPTAL MYECTOMY ON EXERCISE PARAMETERS IN PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: A PROSPECTIVE PAIRED PRE-POST HEMODYNAMIC STRESS ECHOCARDIOGRAPHY STUDY
25. 96-WEEK CARDIAC MAGNETIC RESONANCE (CMR) RESULTS OF TREATMENT WITH MAVACAMTEN FROM THE EXPLORER COHORT OF THE MAVA-LONG-TERM EXTENSION (LTE) STUDY IN PATIENTS (PTS) WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM)
26. LONG-TERM SAFETY AND EFFICACY OF MAVACAMTEN IN PATIENTS (PTS) WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM): UPDATED RESULTS FROM THE PIONEER-OLE STUDY
27. LONG-TERM EFFICACY AND SAFETY OF AFICAMTEN IN PATIENTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
28. TRENDS IN MORTALITY AND MORBIDITY AFTER MYOCARDIAL INFARCTION: A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS BETWEEN 1980-2019
29. CORONARY CONSIDERATIONS FOR THROMBOSIS IN COVID-19 NSTEMI
30. AN EVEN MORE COMPLEX SHONE'S COMPLEX
31. THE EFFECT OF MAVACAMTEN ON CARDIOPULMONARY EXERCISE TESTING PERFORMANCE OF PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY IN EXPLORER-HCM
32. SCREENING FOR TRANSTHYRETIN CARDIAC AMYLOIDOSIS AMONG PATIENTS WITH ATRIAL FIBRILLATION AND LEFT VENTRICULAR HYPERTROPHY
33. DIAGNOSIS-TO-ABLATION TIME AS A PREDICTOR OF ATRIAL FIBRILLATION RECURRENCE
34. CLINICAL AND SOCIOECONOMIC DIFFERENCES AMONG PATIENTS WITH TRANSTHYRETIN CARDIAC AMYLOIDOSIS BELONGING TO NORTH AND SOUTH OF CHICAGO.
35. LONG-TERM SAFETY AND TOLERABILITY OF ACORAMIDIS (AG10) IN SYMPTOMATIC TRANSTHYRETIN AMYLOID CARDIOMYOPATHY: UPDATED ANALYSIS FROM AN ONGOING PHASE 2 OPEN-LABEL EXTENSION STUDY
36. EFFICACY AND SAFETY OF AFICAMTEN AND DISOPYRAMIDE COADMINISTRATION IN OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: RESULTS FROM REDWOOD-HCM COHORT 3
37. SHIFTING OF CALCIUM WITH TAVI CAUSING SUBACUTE CRITICAL LEFT MAIN CORONARY ARTERY STENOSIS REQUIRING CABG
38. A CASE OF CORONARY ARTERY ECTASIA
39. A RARE CASE OF NEONATAL VENTRICULAR TACHYCARDIA
40. WHAT IS BEHIND TAMPONADE? MORTALITY FOLLOWING PERICARDIOCENTESIS
41. RESTORING THE RHYTHM: SUCCESSFUL MANAGEMENT OF ALTERNATING BUNDLE BRANCH BLOCK WITH LEFT BUNDLE BRANCH PACING
42. KOUNIS SYNDROME: ALLERGIC ACUTE CORONARY SYNDROME SECONDARY TO GADOLINIUM CONTRAST
43. A CASE OF SEVERE INTRAVASCULAR HEMOLYSIS: LVOT OBSTRUCTION WITH NORMAL FUNCTIONING BIOPROSTHETIC TAVR VALVE
44. MICROBUBBLE CONTRAST REVEALING THE TALE OF TWO SISTER MASSES IN RIGHT ATRIUM
45. IMPAIRED APICAL LONGITUDINAL STRAIN IS ASSOCIATED WITH ADVERSE EVENTS IN A MULTIETHNIC COHORT WITH APICAL HYPERTROPHIC CARDIOMYOPATHY
46. STANDARD OF CARE MEDICATION PATTERNS OF USE BEFORE AND AFTER SEPTAL MYECTOMY IN PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
47. DEATH TRENDS IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY IN EMERGENCY DEPARTMENTS IN THE UNITED STATES
48. ASSOCIATION BETWEEN BETA BLOCKER USE AND INCIDENCE OF NEW ATRIAL FIBRILLATION AND FLUTTER POST-SEPTAL MYECTOMY FOR OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
49. EFFICACY AND SAFETY OF AFICAMTEN IN THE FIRST COHORT OF PATIENTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY COMPLETING 1-YEAR FOLLOW-UP: FINDINGS FROM THE FOREST-HCM STUDY
50. APPLICATION OF NATURAL LANGUAGE PROCESSING (NLP) IN EARLY DETECTION OF AMYLOIDOSIS: THE ALARM STUDY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.